Area
Reporting and discussion about Science & Medicine, with links to the original sources.
Google DeepMind's AlphaGenome Atlas stores predicted molecular effects for every possible single-letter change in the human genome. On Moonshots, the panel called it the "bulk solution" to variant effect prediction, proposed it as a naming system that could help people with the same rare mutation find each other — and argued about why it is not really a lookup table.
On Moonshots, Peter Diamandis and his panel seized on an exploratory analysis of rentosertib, a drug whose target and molecule were chosen by Insilico Medicine's AI. In 42 patients with a fatal lung disease, blood-protein "aging clocks" shifted a few years younger by week four. The clocks tied to mortality risk did not move significantly, the signal plateaued by week 12, and the study's authors call the result a biomarker finding, not evidence of a longer life.
OpenAI's September 1 announcement lets healthcare organizations connect authorized Epic patient records to ChatGPT, so clinicians can ask what changed since a visit, review labs and medications, and find referrals that were never closed, with summaries pointing back to the chart. On Moonshots with Peter Diamandis, Emad Mostaque called for a sprint to have every health decision double-checked by an AI within a year or two, and Diamandis predicted it would become malpractice to diagnose without AI in the loop — proposals, not current clinical practice.
Philip Johnston spent six months failing to find a cheap trajectory to the nearest star system. A research campaign at the AI physics startup PSI, run on roughly 10 billion tokens and five or six hours of human time, returned an unintuitive answer: slow the spacecraft down first and let it fall toward the sun. The resulting Fermi Explorer mission proposes a 100-kilogram probe, a sub-$15 million budget, a launch by the end of 2029 and a journey of roughly 77,500 years.
On The Diary of a CEO, investor David Friedberg described a cell as a city of 10 billion workers and argued that AI lets researchers screen a million protein ideas on computers before touching a lab bench. His worked example is partial epigenetic reprogramming — and a June 2026 announcement shows that work has reached a first safety trial in human eyes, not restored sight.
GenBio AI's AIDO Cell simulates a human cell that holds its state across a sequence of interventions, and the Moonshots panel watched a demo and began sketching the end of medicine. The article explains what the simulator does today — prioritizing experiments in two prototype cell lines, with laboratory validation of novel predictions still underway — and separates that from the panel's proposals: an AlphaGo-style search from diseased to healthy cells, open public biology data, and frontier labs paying for all of it.
Merck and Moderna said on August 19 that intismeran autogene, an mRNA therapy manufactured separately for every patient, met its main endpoints alongside Keytruda in a 1,137-patient melanoma trial. On the Moonshots podcast, the panel walked through the sequencing-and-machine-learning workflow behind it and argued about whether drug regulation can cope with a treatment that is different for each person.
A colleague told Brian Greene that physicists should choose their final research problems before AI takes over. Greene finds the prospect both exciting and terrifying. His account of three kinds of scientific creativity explains why he thinks machines could make foundational discoveries—and why collaboration might change, rather than simply erase, the human scientist’s role.